Compugen Ltd.

NasdaqCM:CGEN 株式レポート

時価総額:US$143.3m

Compugen 過去の業績

過去 基準チェック /06

Compugenは4%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで19%毎年増加している。売上は成長しており、年平均65.8%の割合である。

主要情報

4.0%

収益成長率

10.8%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率65.8%
株主資本利益率-16.3%
ネット・マージン-22.3%
次回の業績アップデート12 Nov 2024

最近の業績更新

Recent updates

Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues

Aug 22
Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues

Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

May 22
Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

May 01
Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

Apr 05
Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Mar 08
Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans

Feb 17
Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans

Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?

Oct 10
Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?

Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?

Jun 22
Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Sep 21
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Compugen appoints Alberto Sessa as CFO

Sep 12

Compugen gets Japanese patent for COM701, anti-PVRIG antibodies

Aug 24

Compugen Q2 2022 Earnings Preview

Aug 03

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Jun 23
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Mar 02
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Aug 27
Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Jun 28
Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Compugen gains on takeover speculation after iTeos Therapeutics deal

Jun 14

Compugen reports updated COM701 data from Phase 1 study at ASCO21

Jun 08

Compugen's COM902 demonstrates potential benefit in cancer

Apr 27

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 15
Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?

Feb 08
Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?

A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)

Jan 04
A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)

Compugen earns $2M milestone under antibody development deal with AstraZeneca

Dec 23

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 30
Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Compugen Ltd. 2020 Q3 - Results - Earnings Call Presentation

Nov 08

Compugen: Speculative Play For Immuno-Oncology Exposure

Nov 07

Compugen Q3 Earnings Preview

Nov 04

収支内訳

Compugen の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqCM:CGEN 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Jun 2443-101032
31 Mar 2436-171033
31 Dec 2333-191034
30 Sep 238-321031
30 Jun 238-331132
31 Mar 238-331131
31 Dec 228-341131
30 Sep 220-391129
30 Jun 226-341229
31 Mar 226-341229
31 Dec 216-341229
30 Sep 218-341231
30 Jun 212-361128
31 Mar 212-321125
31 Dec 202-301123
30 Sep 200-281019
30 Jun 200-261018
31 Mar 200-261018
31 Dec 190-27920
30 Sep 190-30923
30 Jun 198-27926
31 Mar 198-31930
31 Dec 1818-231030
30 Sep 1818-231030
30 Jun 1810-29930
31 Mar 1810-28929
31 Dec 170-37929
30 Sep 170-36928
30 Jun 170-34926
31 Mar 171-32825
31 Dec 161-32925
30 Sep 169-23824
30 Jun 169-22823
31 Mar 169-23823
31 Dec 159-20721
30 Sep 158-21720
30 Jun 159-20719
31 Mar 1511-15717
31 Dec 1412-11615
30 Sep 148-13613
30 Jun 147-12612
31 Mar 146-13613
31 Dec 134-14612

質の高い収益: CGENは現在利益が出ていません。

利益率の向上: CGENは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: CGENは利益を出していないが、過去 5 年間で年間4%の割合で損失を削減してきた。

成長の加速: CGENの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: CGENは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -2.3% ) と比較することは困難です。


株主資本利益率

高いROE: CGENは現在利益が出ていないため、自己資本利益率 ( -16.33% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘